Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 408

1.

Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial.

Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO.

JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0192. [Epub ahead of print]

PMID:
31021390
2.

James Daniel Cox, MD, FASTRO, FACR.

Wilson JF, Buchholz TA, Komaki R.

Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):784-785. doi: 10.1016/j.ijrobp.2018.09.025. No abstract available. Erratum in: Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):470.

PMID:
30784520
3.

Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer.

Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH.

Clin Lung Cancer. 2019 Mar;20(2):117-123. doi: 10.1016/j.cllc.2018.11.013. Epub 2018 Nov 29.

PMID:
30611672
4.

Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis.

Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH.

Radiat Oncol. 2018 Dec 29;13(1):258. doi: 10.1186/s13014-018-1205-9.

5.

An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy.

Konski A, Bhargavan M, Owen J, Komaki R, Langer CJ, Gore E, Paulus R, Choy H, Bruner DW, Curran WJ.

J Radiat Oncol. 2018 Jun;7(2):195-201. doi: 10.1007/s13566-018-0346-7. Epub 2018 Mar 10.

6.

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.

Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, Timmerman RD, Komaki RR, Urbanic JJ, Stephans KL, Yom SS, Robinson CG, Belani CP, Iyengar P, Ajlouni MI, Gopaul DD, Gomez Suescun JB, McGarry RC, Choy H, Bradley JD.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084. doi: 10.1016/j.ijrobp.2018.11.051. Epub 2018 Dec 1.

PMID:
30513377
7.

A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.

Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, Thomas CR, Edelman MJ, Horn L, Komaki R, Cohen HJ, Kishor Ganti A, Pang H, Wang X.

Cancer. 2019 Feb 1;125(3):382-390. doi: 10.1002/cncr.31813. Epub 2018 Oct 21.

PMID:
30343497
8.

Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis.

Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH.

Clin Lung Cancer. 2018 Nov;19(6):e885-e891. doi: 10.1016/j.cllc.2018.08.012. Epub 2018 Aug 22.

PMID:
30197263
9.

Anticancer therapy and lung injury: molecular mechanisms.

Li L, Mok H, Jhaveri P, Bonnen MD, Sikora AG, Eissa NT, Komaki RU, Ghebre YT.

Expert Rev Anticancer Ther. 2018 Oct;18(10):1041-1057. doi: 10.1080/14737140.2018.1500180. Epub 2018 Jul 23. Review.

PMID:
29996062
10.

Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.

Boonyawan K, Gomez DR, Komaki R, Xu Y, Nantavithya C, Allen PK, Mohan R, Liao Z.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):919-926. doi: 10.1016/j.ijrobp.2018.04.012. Epub 2018 Apr 12.

PMID:
29976504
11.

Hematologic variables associated with brain failure in patients with small-cell lung cancer.

Suzuki R, Wei X, Allen PK, Welsh JW, Komaki R, Lin SH.

Radiother Oncol. 2018 Sep;128(3):505-512. doi: 10.1016/j.radonc.2018.05.026. Epub 2018 Jun 12.

PMID:
29907337
12.

Is prophylactic cranial irradiation indicated for patients with extensive-stage small cell lung cancer with a complete response to first-line treatment?

Suzuki R, Komaki R.

Radiother Oncol. 2018 Jun;127(3):339-343. doi: 10.1016/j.radonc.2018.03.034. Epub 2018 May 7.

PMID:
29747874
13.

Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer.

Yang J, Xu T, Gomez DR, Yuan X, Nguyen QN, Jeter M, Song Y, Komaki R, Hu Y, Hahn SM, Liao Z.

Cancer Med. 2018 Jun;7(6):2247-2255. doi: 10.1002/cam4.1349. Epub 2018 May 9.

14.

Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA.

Oncology. 2018;94(6):345-353. doi: 10.1159/000486720. Epub 2018 Apr 27.

15.

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer.

Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):558-563. doi: 10.1016/j.ijrobp.2018.02.022. Epub 2018 Mar 2.

PMID:
29680255
16.

Association of lung fluorodeoxyglucose uptake with radiation pneumonitis after concurrent chemoradiation for non-small cell lung cancer.

Yue J, McKeever M, Sio TT, Xu T, Huo J, Shi Q, Nguyen QN, Komaki R, Gomez DR, Pan T, Wang XS, Liao Z.

Clin Transl Radiat Oncol. 2017 May 11;4:1-7. doi: 10.1016/j.ctro.2017.04.001. eCollection 2017 Jun.

17.

Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study.

Yue J, Shi Q, Xu T, Jeter M, Chen TY, Komaki R, Gomez DR, Pan T, Cleeland CS, Liao Z, Wang XS.

Qual Life Res. 2018 Jun;27(6):1563-1570. doi: 10.1007/s11136-018-1834-3. Epub 2018 Mar 16.

18.

My Path from Hiroshima to Houston.

Komaki R.

Pract Radiat Oncol. 2019 Jan;9(1):1-2. doi: 10.1016/j.prro.2017.10.006. Epub 2017 Oct 14. No abstract available.

PMID:
29477715
19.

Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy.

Wen J, Liu H, Wang L, Wang X, Gu N, Liu Z, Xu T, Gomez DR, Komaki R, Liao Z, Wei Q.

J Thorac Oncol. 2018 May;13(5):660-675. doi: 10.1016/j.jtho.2018.01.028. Epub 2018 Feb 15.

20.

Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer.

Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R.

Radiother Oncol. 2018 Mar;126(3):499-505. doi: 10.1016/j.radonc.2017.12.030. Epub 2018 Feb 2.

21.

Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer.

Pezzi TA, Schwartz DL, Mohamed ASR, Welsh JW, Komaki RU, Hahn SM, Sepesi B, Pezzi CM, Fuller CD, Chun SG.

JAMA Oncol. 2018 Aug 1;4(8):e174504. doi: 10.1001/jamaoncol.2017.4504. Epub 2018 Aug 9.

22.

Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR Jr, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R.

J Clin Oncol. 2018 Jun 20;36(18):1813-1822. doi: 10.1200/JCO.2017.74.0720. Epub 2018 Jan 2.

23.

Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis.

Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum MA, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani JA, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Nov 1;99(3):667-676. doi: 10.1016/j.ijrobp.2017.06.2450. Epub 2017 Jun 27.

PMID:
29280461
24.

Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.

Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH.

Radiother Oncol. 2018 Jul;128(1):154-160. doi: 10.1016/j.radonc.2017.11.028. Epub 2017 Dec 14.

25.

Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.

Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):730-737. doi: 10.1016/j.ijrobp.2017.10.042. Epub 2017 Nov 3.

26.

Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.

Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Br J Cancer. 2018 Feb 6;118(3):331-337. doi: 10.1038/bjc.2017.423. Epub 2017 Dec 12.

27.

Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Target Oncol. 2018 Feb;13(1):99-106. doi: 10.1007/s11523-017-0540-3.

28.

Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy.

Zhou R, Xu T, Nguyen QN, Liu Y, Yang J, Komaki R, Gomez DR, Liao Z.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):452-461. doi: 10.1016/j.ijrobp.2017.10.003. Epub 2017 Oct 12.

PMID:
29174428
29.

Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus.

Xu C, Xi M, Komaki R, Balter PA, Huang M, Hobbs BP, Wang L, Lin SH.

Adv Radiat Oncol. 2017 Mar 27;2(3):325-332. doi: 10.1016/j.adro.2017.03.006. eCollection 2017 Jul-Sep.

30.

Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study.

Shi A, Liao Z, Allen PK, Ho L, Murphy MB, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH.

Adv Radiat Oncol. 2017 Apr 19;2(3):316-324. doi: 10.1016/j.adro.2017.04.002. eCollection 2017 Jul-Sep.

31.

Prophylactic Cranial Irradiation Following Surgical Resection of Early-Stage Small-Cell Lung Cancer: A Review of the Literature.

Bloom BC, Augustyn A, Sepesi B, Patel S, Shah SJ, Komaki RU, Schild SE, Chun SG.

Front Oncol. 2017 Sep 29;7:228. doi: 10.3389/fonc.2017.00228. eCollection 2017. Review.

32.

RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Non-small Cell Lung Cancer.

Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs BP, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach JV, Lin SH.

Clin Cancer Res. 2018 Jan 15;24(2):341-350. doi: 10.1158/1078-0432.CCR-17-1455. Epub 2017 Oct 13.

33.

Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.

Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH.

Radiother Oncol. 2017 Oct;125(1):48-54. doi: 10.1016/j.radonc.2017.07.034. Epub 2017 Sep 13.

PMID:
28917586
34.

Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.

Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA.

Cancer. 2017 Nov 1;123(21):4106-4113. doi: 10.1002/cncr.30953. Epub 2017 Sep 8.

35.

Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer.

Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):407-416. doi: 10.1016/j.ijrobp.2017.05.050. Epub 2017 Jun 6.

PMID:
28871991
36.

Reirradiation of thoracic cancers with intensity modulated proton therapy.

Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):58-65. doi: 10.1016/j.prro.2017.07.002. Epub 2017 Jul 8.

PMID:
28867546
37.

Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.

Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):128-135. doi: 10.1016/j.ijrobp.2017.05.037. Epub 2017 Jun 1.

PMID:
28816138
38.

Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.

Kono M, Allen PK, Lin SH, Wei X, Jeter MD, Welsh JW, Cox JD, Komaki R.

J Thorac Oncol. 2017 Nov;12(11):1696-1703. doi: 10.1016/j.jtho.2017.07.030. Epub 2017 Aug 10.

39.

Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.

Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD.

JAMA Oncol. 2017 Aug 10;3(8):e172032. doi: 10.1001/jamaoncol.2017.2032. Epub 2017 Aug 10. Erratum in: JAMA Oncol. 2017 Dec 1;3(12):1742. JAMA Oncol. 2017 Sep 1;3(9):1286.

40.

The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy.

Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, Bhutani MS, Lee JH, Weston B, Komaki R, Lin SH.

Radiother Oncol. 2017 Aug;124(2):318-324. doi: 10.1016/j.radonc.2017.06.019. Epub 2017 Jul 4.

PMID:
28687396
41.

Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.

Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang CM, Lin SH.

Clin Cancer Res. 2017 Oct 1;23(19):5948-5958. doi: 10.1158/1078-0432.CCR-17-0802. Epub 2017 Jul 5.

42.

Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma.

Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH.

Ann Surg. 2018 Aug;268(2):289-295. doi: 10.1097/SLA.0000000000002352.

PMID:
28628563
43.

Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old.

Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang M, Komaki R, Lin SH.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):811-819. doi: 10.1016/j.ijrobp.2017.02.097. Epub 2017 Mar 1.

PMID:
28602412
44.

18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.

Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH.

J Nucl Med. 2017 Nov;58(11):1756-1763. doi: 10.2967/jnumed.117.192591. Epub 2017 May 18.

45.

A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients.

Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, James SE, Evans JD, Spears GM, Komaki R, Haddock MG, Mehta MP, Hallemeier CL, Merrell KW.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):820-828. doi: 10.1016/j.ijrobp.2017.02.021. Epub 2017 Feb 20.

PMID:
28476435
46.

Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.

Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta MP, Liao Z, Cox JD, Komaki R, Mehran RJ, Chuong MD, Hallemeier CL.

Radiother Oncol. 2017 Jun;123(3):376-381. doi: 10.1016/j.radonc.2017.04.013. Epub 2017 Apr 25.

PMID:
28455153
47.

Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2017 Apr;15(4):504-535.

PMID:
28404761
48.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer.

Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH.

J Thorac Oncol. 2017 Jun;12(6):1001-1010. doi: 10.1016/j.jtho.2017.03.017. Epub 2017 Mar 27.

49.

7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.

Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY.

Cancer. 2017 Aug 15;123(16):3031-3039. doi: 10.1002/cncr.30693. Epub 2017 Mar 27.

50.

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.

Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY.

J Thorac Oncol. 2017 Jun;12(6):983-992. doi: 10.1016/j.jtho.2017.02.018. Epub 2017 Mar 1.

Supplemental Content

Loading ...
Support Center